Gender differences in the effects of cardiovascular drugs

J Tamargo, G Rosano, T Walther, J Duarte, A Niessner, J C Kaski, C Ceconi, H Drexel, K Kjeldsen, G Savarese, C Torp-Pedersen, D Atar, B S Lewis, S Agewall

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

Although sex-specific differences in cardiovascular medicine are well known, the exact influences of sex on the effect of cardiovascular drugs remain unclear. Women and men differ in body composition and physiology (hormonal influences during the menstrual cycle, menopause, and pregnancy) and they present differences in drug pharmacokinetics (absorption, distribution, metabolism, and excretion) and pharmacodynamics, so that is not rare that they may respond differently to cardiovascular drugs. Furthermore, women are also less often treated with evidence-based drugs thereby preventing optimization of therapeutics for women of all ages, experience more relevant adverse drug reactions than men, and remain underrepresented in most clinical trials. Thus, current guidelines for prevention, diagnosis, and medical treatment for cardiovascular diseases are based on trials conducted predominantly in middle-aged men. A better understanding of these sex-related differences is fundamental to improve the safety and efficacy of cardiovascular drugs and for developing proper individualized cardiovascular therapeutic strategies both in men and women. This review briefly summarizes gender differences in the pharmacokinetics and pharmacodynamics of cardiovascular drugs and provides recommendations to close the gaps in our understanding of sex-specific differences in drug efficacy and safety.

Original languageEnglish
Pages (from-to)163-182
Number of pages20
JournalEuropean heart journal. Cardiovascular pharmacotherapy
Volume3
Issue number3
DOIs
Publication statusPublished - Jul 1 2017

Fingerprint

Cardiovascular Agents
Sex Characteristics
Pharmacokinetics
Pharmaceutical Preparations
Safety
Menstrual Cycle
Menopause
Body Composition
Drug-Related Side Effects and Adverse Reactions
Cardiovascular Diseases
Therapeutics
Medicine
Clinical Trials
Guidelines
Pregnancy

Cite this

Tamargo, J., Rosano, G., Walther, T., Duarte, J., Niessner, A., Kaski, J. C., ... Agewall, S. (2017). Gender differences in the effects of cardiovascular drugs. European heart journal. Cardiovascular pharmacotherapy, 3(3), 163-182. https://doi.org/10.1093/ehjcvp/pvw042

Gender differences in the effects of cardiovascular drugs. / Tamargo, J; Rosano, G; Walther, T; Duarte, J; Niessner, A; Kaski, J C; Ceconi, C; Drexel, H; Kjeldsen, K; Savarese, G; Torp-Pedersen, C; Atar, D; Lewis, B S; Agewall, S.

In: European heart journal. Cardiovascular pharmacotherapy, Vol. 3, No. 3, 01.07.2017, p. 163-182.

Research output: Contribution to journalReview article

Tamargo, J, Rosano, G, Walther, T, Duarte, J, Niessner, A, Kaski, JC, Ceconi, C, Drexel, H, Kjeldsen, K, Savarese, G, Torp-Pedersen, C, Atar, D, Lewis, BS & Agewall, S 2017, 'Gender differences in the effects of cardiovascular drugs', European heart journal. Cardiovascular pharmacotherapy, vol. 3, no. 3, pp. 163-182. https://doi.org/10.1093/ehjcvp/pvw042
Tamargo, J ; Rosano, G ; Walther, T ; Duarte, J ; Niessner, A ; Kaski, J C ; Ceconi, C ; Drexel, H ; Kjeldsen, K ; Savarese, G ; Torp-Pedersen, C ; Atar, D ; Lewis, B S ; Agewall, S. / Gender differences in the effects of cardiovascular drugs. In: European heart journal. Cardiovascular pharmacotherapy. 2017 ; Vol. 3, No. 3. pp. 163-182.
@article{f2fc4008397346a4a2c663058a39f7db,
title = "Gender differences in the effects of cardiovascular drugs",
abstract = "Although sex-specific differences in cardiovascular medicine are well known, the exact influences of sex on the effect of cardiovascular drugs remain unclear. Women and men differ in body composition and physiology (hormonal influences during the menstrual cycle, menopause, and pregnancy) and they present differences in drug pharmacokinetics (absorption, distribution, metabolism, and excretion) and pharmacodynamics, so that is not rare that they may respond differently to cardiovascular drugs. Furthermore, women are also less often treated with evidence-based drugs thereby preventing optimization of therapeutics for women of all ages, experience more relevant adverse drug reactions than men, and remain underrepresented in most clinical trials. Thus, current guidelines for prevention, diagnosis, and medical treatment for cardiovascular diseases are based on trials conducted predominantly in middle-aged men. A better understanding of these sex-related differences is fundamental to improve the safety and efficacy of cardiovascular drugs and for developing proper individualized cardiovascular therapeutic strategies both in men and women. This review briefly summarizes gender differences in the pharmacokinetics and pharmacodynamics of cardiovascular drugs and provides recommendations to close the gaps in our understanding of sex-specific differences in drug efficacy and safety.",
author = "J Tamargo and G Rosano and T Walther and J Duarte and A Niessner and Kaski, {J C} and C Ceconi and H Drexel and K Kjeldsen and G Savarese and C Torp-Pedersen and D Atar and Lewis, {B S} and S Agewall",
note = "Published on behalf of the European Society of Cardiology. All rights reserved. {\circledC} The Author 2017. For Permissions, please email: journals.permissions@oup.com.",
year = "2017",
month = "7",
day = "1",
doi = "10.1093/ehjcvp/pvw042",
language = "English",
volume = "3",
pages = "163--182",
journal = "European heart journal. Cardiovascular pharmacotherapy",
issn = "2055-6837",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Gender differences in the effects of cardiovascular drugs

AU - Tamargo, J

AU - Rosano, G

AU - Walther, T

AU - Duarte, J

AU - Niessner, A

AU - Kaski, J C

AU - Ceconi, C

AU - Drexel, H

AU - Kjeldsen, K

AU - Savarese, G

AU - Torp-Pedersen, C

AU - Atar, D

AU - Lewis, B S

AU - Agewall, S

N1 - Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. For Permissions, please email: journals.permissions@oup.com.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Although sex-specific differences in cardiovascular medicine are well known, the exact influences of sex on the effect of cardiovascular drugs remain unclear. Women and men differ in body composition and physiology (hormonal influences during the menstrual cycle, menopause, and pregnancy) and they present differences in drug pharmacokinetics (absorption, distribution, metabolism, and excretion) and pharmacodynamics, so that is not rare that they may respond differently to cardiovascular drugs. Furthermore, women are also less often treated with evidence-based drugs thereby preventing optimization of therapeutics for women of all ages, experience more relevant adverse drug reactions than men, and remain underrepresented in most clinical trials. Thus, current guidelines for prevention, diagnosis, and medical treatment for cardiovascular diseases are based on trials conducted predominantly in middle-aged men. A better understanding of these sex-related differences is fundamental to improve the safety and efficacy of cardiovascular drugs and for developing proper individualized cardiovascular therapeutic strategies both in men and women. This review briefly summarizes gender differences in the pharmacokinetics and pharmacodynamics of cardiovascular drugs and provides recommendations to close the gaps in our understanding of sex-specific differences in drug efficacy and safety.

AB - Although sex-specific differences in cardiovascular medicine are well known, the exact influences of sex on the effect of cardiovascular drugs remain unclear. Women and men differ in body composition and physiology (hormonal influences during the menstrual cycle, menopause, and pregnancy) and they present differences in drug pharmacokinetics (absorption, distribution, metabolism, and excretion) and pharmacodynamics, so that is not rare that they may respond differently to cardiovascular drugs. Furthermore, women are also less often treated with evidence-based drugs thereby preventing optimization of therapeutics for women of all ages, experience more relevant adverse drug reactions than men, and remain underrepresented in most clinical trials. Thus, current guidelines for prevention, diagnosis, and medical treatment for cardiovascular diseases are based on trials conducted predominantly in middle-aged men. A better understanding of these sex-related differences is fundamental to improve the safety and efficacy of cardiovascular drugs and for developing proper individualized cardiovascular therapeutic strategies both in men and women. This review briefly summarizes gender differences in the pharmacokinetics and pharmacodynamics of cardiovascular drugs and provides recommendations to close the gaps in our understanding of sex-specific differences in drug efficacy and safety.

U2 - 10.1093/ehjcvp/pvw042

DO - 10.1093/ehjcvp/pvw042

M3 - Review article

C2 - 28329228

VL - 3

SP - 163

EP - 182

JO - European heart journal. Cardiovascular pharmacotherapy

JF - European heart journal. Cardiovascular pharmacotherapy

SN - 2055-6837

IS - 3

ER -